Medication info
Duo Well A Tablets 80/5/5 mg

Duo Well A Tablets 80/5/5 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/box [6 tablets/PTP X 5]
Approval status
Active

MFDS item code 201804682 · Approved 2018.11.27 · Insurance code 642105330

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin alone, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, a direct switch to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In elderly patients aged 75 years or older, clearance of amlodipine is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/5 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.3-fold and AUC increased approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor the patient closely.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication helps effectively lower blood pressure in patients with essential hypertension who have difficulty in blood pressure control even when using a combination of telmisartan and amlodipine. Additionally, rosuvastatin improves hypercholesterolemia and dyslipidemia by lowering bad cholesterol (LDL) levels in the blood and delaying the progression of atherosclerosis. It also assists in the dietary management of patients with familial hypercholesterolemia and is used to reduce the risk of cardiovascular complications such as stroke and myocardial infarction in patients at high risk of cardiovascular disease. Therefore, this medication is highly effective for patients who require simultaneous management of blood pressure and blood lipids, and it helps improve overall cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin alone, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, a direct switch to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In elderly patients aged 75 years or older, clearance of amlodipine is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/5 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.3-fold and AUC increased approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk due to the increase in rosuvastatin Cmax and monitor the patient closely.

Precautions

This medication may cause serious harm or death to the fetus and newborn when administered to pregnant women; thus, discontinuation is necessary immediately upon confirmation of pregnancy. This medication should not be used in patients with a history of allergies to any active ingredient or components, pregnant or potentially pregnant women, nursing mothers, or patients with severely impaired liver or kidney function. Furthermore, it is contraindicated in diabetic patients with moderate to severe kidney impairment or when combined with specific drugs. Patients with very low blood pressure, elderly patients, those with elevated potassium levels, or patients with compromised liver function should use this medication cautiously, and muscle-related side effects should be monitored just like with any other statin. If symptoms of muscle pain or weakness occur during treatment, it is imperative to inform a healthcare professional immediately and conduct blood tests if necessary to check for muscle injury. Periodic liver function tests are recommended to monitor any abnormalities in liver function. Various side effects have been reported with this medication, common ones including headache, dizziness, dyspepsia, and peripheral edema, while serious allergic reactions, muscle injury, or liver function abnormalities may occur rarely. It is crucial to take this medication as prescribed by a physician and to seek advice immediately if any unusual symptoms develop.

Side effects

  • Viral upper respiratory tract infection
  • conjunctivitis
  • peripheral edema
  • chest discomfort
  • dizziness
  • abdominal pain
  • duodenitis
  • arthralgia
  • disc herniation
  • spinal canal stenosis
Show 152 more
  • tinnitus
  • increased ALT
  • increased AST
  • increased ALP
  • increased γ-GTP
  • chronic gastritis
  • hiatal hernia
  • musculoskeletal pain
  • neck pain
  • nasopharyngitis
  • upper abdominal discomfort
  • upper abdominal pain
  • positional dizziness
  • dysuria
  • rhinitis
  • oropharyngeal discomfort
  • lung disease
  • unspecified gastrointestinal disease
  • benign gastric neoplasm
  • hemorrhoids
  • skeletal pain
  • osteoporosis
  • sensory reduction
  • movement disorders
  • atherosclerosis
  • frequent urination
  • ear ringing
  • hearing loss
  • halitosis
  • fatty liver
  • influenza-like symptoms
  • dyspepsia
  • myalgia
  • urinary tract infection
  • headache
  • pain
  • fatigue
  • cough
  • hypertension
  • chest pain
  • nausea
  • erectile dysfunction
  • low back pain
  • muscle cramps
  • myalgia
  • bradycardia
  • eosinophilia
  • thrombocytopenia
  • increased uric acid
  • liver dysfunction
  • liver disease
  • acute kidney failure
  • renal impairment
  • anemia
  • increased CPK
  • anaphylactic reaction
  • tendon pain
  • vascular edema
  • erectile dysfunction
  • increased sweating
  • flushing
  • allergy
  • fever
  • leg pain
  • malaise
  • palpitations
  • dependency edema
  • angina
  • rapid pulse
  • leg edema
  • abnormal ECG
  • insomnia
  • drowsiness
  • migraine
  • vertigo
  • sensory disturbance
  • involuntary muscle contractions
  • sensory reduction
  • flatulence
  • constipation
  • gastritis
  • vomiting
  • dry mouth
  • hemorrhoids
  • gastroenteritis
  • enteritis
  • gastroesophageal reflux
  • toothache
  • nonspecific gastrointestinal disease
  • gout
  • hypercholesterolemia
  • diabetes
  • arthritis
  • arthralgia
  • leg numbness
  • anxiety
  • depression
  • neuroexcitability
  • infection
  • fungal infection
  • abscess
  • otitis media
  • asthma
  • bronchitis
  • rhinitis
  • dyspnea
  • epistaxis
  • dermatitis
  • rash
  • eczema
  • itching
  • frequent urination
  • cystitis
  • cerebrovascular disease
  • visual disturbances
  • conjunctivitis
  • ear ringing
  • ear pain
  • vascular edema
  • headache
  • weakness
  • frailty
  • facial edema
  • lower limb edema
  • vascular edema
  • itching
  • hypersensitivity reaction
  • increased sweating
  • erythema
  • chest pain
  • atrial fibrillation
  • congestive heart failure
  • myocardial infarction
  • increased blood pressure
  • worsening hypertension
  • hypotension
  • hyperkalemia
  • hypoglycemia
  • syncope
  • diarrhea
  • muscle cramps
  • myalgia
  • thrombocytopenia
  • increased uric acid
  • liver dysfunction
  • liver disease
  • acute kidney failure
  • renal impairment
  • anemia
  • increased CPK
  • anaphylactic reaction
  • tendon pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to light; hence, it should be stored in a container that blocks light effectively. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius to ensure the preservation of its effectiveness and safety.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/box [6 tablets/PTP X 5]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.